{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T10:49:55Z","timestamp":1758192595803,"version":"3.44.0"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T00:00:00Z","timestamp":1748131200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001321","name":"National Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002701","name":"Ministry of Education","doi-asserted-by":"publisher","award":["2020R1I1A2075060","2022R1F1A1074989","2022R1A4A5031503"],"award-info":[{"award-number":["2020R1I1A2075060","2022R1F1A1074989","2022R1A4A5031503"]}],"id":[{"id":"10.13039\/501100002701","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.biopha.2025.118215","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T06:29:42Z","timestamp":1748327382000},"page":"118215","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Azvudine exhibits potent differentiation-inducing effect by targeting the TERT\/p21 axis in acute myeloid leukemia"],"prefix":"10.1016","volume":"188","author":[{"given":"Chan-Seong","family":"Kwon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji-Eun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byeol-Eun","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae-Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6364-2148","authenticated-orcid":false,"given":"Sang-Hun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ho-Jin","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-Woo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.biopha.2025.118215_bib1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/ijlh.13135","article-title":"How I investigate acute myeloid leukemia","volume":"42","author":"Narayanan","year":"2020","journal-title":"Int J. Lab Hematol."},{"key":"10.1016\/j.biopha.2025.118215_bib2","doi-asserted-by":"crossref","DOI":"10.1159\/000536152","article-title":"Pathophysiology of acute myeloid leukemia (AML)","author":"Wachter","year":"2024","journal-title":"Acta Haematol."},{"key":"10.1016\/j.biopha.2025.118215_bib3","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","article-title":"Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges","volume":"36","author":"Shallis","year":"2019","journal-title":"Blood Rev."},{"issue":"16","key":"10.1016\/j.biopha.2025.118215_bib4","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1080\/14656566.2017.1391216","article-title":"Cytarabine and daunorubicin for the treatment of acute myeloid leukemia","volume":"18","author":"Murphy","year":"2017","journal-title":"Expert Opin. Pharm."},{"issue":"11","key":"10.1016\/j.biopha.2025.118215_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10110429","article-title":"Novel agents for acute myeloid leukemia","volume":"10","author":"Luppi","year":"2018","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.biopha.2025.118215_bib6","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s12185-013-1334-8","article-title":"FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance","volume":"97","author":"Grunwald","year":"2013","journal-title":"Int J. Hematol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118215_bib7","doi-asserted-by":"crossref","first-page":"13","DOI":"10.5045\/br.2021.2021152","article-title":"IDH 1\/2 mutations in acute myeloid leukemia","volume":"57","author":"Byun","year":"2022","journal-title":"Blood Res"},{"issue":"1","key":"10.1016\/j.biopha.2025.118215_bib8","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.biopha.2025.118215_bib9","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/s41408-021-00584-3","article-title":"Differentiation therapy for myeloid malignancies: beyond cytotoxicity","volume":"11","author":"Stubbins","year":"2021","journal-title":"Blood Cancer J."},{"issue":"1","key":"10.1016\/j.biopha.2025.118215_bib10","first-page":"26","article-title":"Differentiation therapy of myeloid leukemia: four decades of development","volume":"106","author":"Madan","year":"2021","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.biopha.2025.118215_bib11","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.ccell.2017.10.002","article-title":"Acute promyelocytic leukemia: a paradigm for oncoprotein-targeted cure","volume":"32","author":"de Th\u00e9","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.biopha.2025.118215_bib12","article-title":"Roles of histone deacetylases in acute myeloid leukemia with fusion proteins","volume":"11","author":"Zhang","year":"2021","journal-title":"Front Oncol."},{"issue":"2","key":"10.1016\/j.biopha.2025.118215_bib13","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41408-021-00425-3","article-title":"Acute myeloid leukemia: current progress and future directions","volume":"11","author":"Kantarjian","year":"2021","journal-title":"Blood Cancer J."},{"issue":"34","key":"10.1016\/j.biopha.2025.118215_bib14","doi-asserted-by":"crossref","first-page":"6172","DOI":"10.1038\/s41388-019-0872-9","article-title":"Mechanisms underlying the activation of TERT transcription and telomerase activity in human cancer: old actors and new players","volume":"38","author":"Yuan","year":"2019","journal-title":"Oncogene"},{"issue":"7","key":"10.1016\/j.biopha.2025.118215_bib15","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/s41580-020-0234-z","article-title":"Regulation of human telomerase in homeostasis and disease","volume":"21","author":"Roake","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"13","key":"10.1016\/j.biopha.2025.118215_bib16","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1134\/S0006297910130055","article-title":"Telomerase: structure, functions, and activity regulation","volume":"75","author":"Zvereva","year":"2010","journal-title":"Biochem. (Mosc."},{"issue":"16","key":"10.1016\/j.biopha.2025.118215_bib17","doi-asserted-by":"crossref","first-page":"4302","DOI":"10.1182\/bloodadvances.2023009903","article-title":"Telomerase-targeted therapies in myeloid malignancies","volume":"7","author":"Waksal","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.biopha.2025.118215_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.589929","article-title":"TERT-regulation and roles in cancer formation","volume":"11","author":"Dratwa","year":"2020","journal-title":"Front Immunol."},{"issue":"7","key":"10.1016\/j.biopha.2025.118215_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11071923","article-title":"Imetelstat Induces Leukemia Stem Cell Death in Pediatric Acute Myeloid Leukemia Patient-Derived Xenografts","volume":"11","author":"Barwe","year":"2022","journal-title":"J. Clin. Med"},{"issue":"1","key":"10.1016\/j.biopha.2025.118215_bib20","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s43018-023-00653-5","article-title":"Imetelstat-mediated alterations in fatty acid metabolism to induce ferroptosis as a therapeutic strategy for acute myeloid leukemia","volume":"5","author":"Bruedigam","year":"2024","journal-title":"Nat. Cancer"},{"issue":"10423","key":"10.1016\/j.biopha.2025.118215_bib21","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(23)01724-5","article-title":"Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"403","author":"Platzbecker","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2025.118215_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.820647","article-title":"FNC: An Advanced Anticancer Therapeutic or Just an Underdog?","volume":"12","author":"Fayzullina","year":"2022","journal-title":"Front Oncol."},{"issue":"6","key":"10.1016\/j.biopha.2025.118215_bib23","article-title":"The first Chinese oral anti-COVID-19 drug Azvudine launched","volume":"3","author":"Yu","year":"2022","journal-title":"Innov. (Camb. )"},{"issue":"1","key":"10.1016\/j.biopha.2025.118215_bib24","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/s41392-021-00835-6","article-title":"Azvudine is a thymus-homing anti-SARS-CoV-2 drug effective in treating COVID-19 patients","volume":"6","author":"Zhang","year":"2021","journal-title":"Signal Transduct. Target Ther."},{"issue":"1","key":"10.1016\/j.biopha.2025.118215_bib25","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.cell.2016.08.057","article-title":"Inhibition of dihydroorotate dehydrogenase overcomes differentiation blockade in acute myeloid leukemia","volume":"167","author":"Sykes","year":"2016","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.biopha.2025.118215_bib26","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1038\/s41375-019-0492-y","article-title":"Disruption of the Myc-PDE4B regulatory circuitry impairs B-cell lymphoma survival","volume":"33","author":"Nam","year":"2019","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.biopha.2025.118215_bib27","doi-asserted-by":"crossref","DOI":"10.3390\/genes13050883","article-title":"Genome-Wide Gene Expression Profiling Defines the Mechanism of Anticancer Effect of Colorectal Cancer Cell-Derived Conditioned Medium on Acute Myeloid Leukemia","volume":"13","author":"Lee","year":"2022","journal-title":"Genes (Basel)"},{"issue":"7","key":"10.1016\/j.biopha.2025.118215_bib28","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1096\/fj.09-136895","article-title":"Elevated CO2 selectively inhibits interleukin-6 and tumor necrosis factor expression and decreases phagocytosis in the macrophage","volume":"24","author":"Wang","year":"2010","journal-title":"FASEB J."},{"issue":"1","key":"10.1016\/j.biopha.2025.118215_bib29","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1159\/000351587","article-title":"Thymosin \u03b11 activates complement receptor-mediated phagocytosis in human monocyte-derived macrophages","volume":"6","author":"Serafino","year":"2014","journal-title":"J. Innate Immun."},{"issue":"5","key":"10.1016\/j.biopha.2025.118215_bib30","doi-asserted-by":"crossref","first-page":"4580","DOI":"10.3390\/cimb46050278","article-title":"Nakai) K. Bremer and humphries extract limits MYC Expression to Induce Apoptosis in Diffuse Large B Cell Lymphoma","volume":"46","author":"Woo","year":"2024","journal-title":"Curr. Issues Mol. Biol."},{"issue":"5","key":"10.1016\/j.biopha.2025.118215_bib31","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.3390\/cimb45050257","article-title":"Anti-Leukemic Effects of","volume":"45","author":"Kwon","year":"2023","journal-title":"Curr. Issues Mol. Biol."},{"issue":"12","key":"10.1016\/j.biopha.2025.118215_bib32","first-page":"7177","article-title":"An improved and versatile immunosuppression protocol for the development of tumor xenograft in mice","volume":"34","author":"Jivrajani","year":"2014","journal-title":"Anticancer Res"},{"issue":"2","key":"10.1016\/j.biopha.2025.118215_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/mps3020027","article-title":"An Optimised Step-by-Step Protocol for Measuring Relative Telomere Length","volume":"3","author":"Joglekar","year":"2020","journal-title":"Methods Protoc."},{"issue":"7","key":"10.1016\/j.biopha.2025.118215_bib34","doi-asserted-by":"crossref","first-page":"4888","DOI":"10.18632\/oncotarget.2917","article-title":"The DNA methylation inhibitor induces telomere dysfunction and apoptosis of leukemia cells that is attenuated by telomerase over-expression","volume":"6","author":"Zhang","year":"2015","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.biopha.2025.118215_bib35","doi-asserted-by":"crossref","first-page":"60","DOI":"10.2174\/1874467213666200512080122","article-title":"Azacitidine, as a DNMT Inhibitor Decreases hTERT Gene Expression and Telomerase Activity More Effective Compared with HDAC Inhibitor in Human Head and Neck Squamous Cell Carcinoma Cell Lines","volume":"14","author":"Atri","year":"2021","journal-title":"Curr. Mol. Pharm."},{"issue":"8","key":"10.1016\/j.biopha.2025.118215_bib36","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/gcc.21962","article-title":"Differential TERT promoter methylation and response to 5-aza-2\u2032-deoxycytidine in acute myeloid leukemia cell lines: TERT expression, telomerase activity, telomere length, and cell death","volume":"51","author":"Pettigrew","year":"2012","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.biopha.2025.118215_bib37","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3389\/fonc.2012.00133","article-title":"Telomere-independent functions of telomerase in nuclei, cytoplasm, and mitochondria","volume":"2","author":"Chiodi","year":"2012","journal-title":"Front Oncol."},{"issue":"4","key":"10.1016\/j.biopha.2025.118215_bib38","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11041091","article-title":"Multiple actions of telomerase reverse transcriptase in cell death regulation","volume":"11","author":"Palamarchuk","year":"2023","journal-title":"Biomedicines"},{"issue":"4","key":"10.1016\/j.biopha.2025.118215_bib39","doi-asserted-by":"crossref","DOI":"10.3390\/cells12040659","article-title":"Doxorubicin-An Agent with Multiple Mechanisms of Anticancer Activity","volume":"12","author":"Kciuk","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.biopha.2025.118215_bib40","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.fob.2015.09.008","article-title":"Induced myelomonocytic differentiation in leukemia cells is accompanied by noncanonical transcription factor expression","volume":"5","author":"Jensen","year":"2015","journal-title":"FEBS Open Bio"},{"key":"10.1016\/j.biopha.2025.118215_bib41","first-page":"41","article-title":"The HL60 cell line: a model system for studying human myeloid cell differentiation","volume":"9","author":"Birnie","year":"1988","journal-title":"Br. J. Cancer Suppl."},{"issue":"1","key":"10.1016\/j.biopha.2025.118215_bib42","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/sj.cdd.4400771","article-title":"A functionally active RARalpha nuclear receptor is expressed in retinoic acid non responsive early myeloblastic cell lines","volume":"8","author":"Grande","year":"2001","journal-title":"Cell Death Differ."},{"issue":"1","key":"10.1016\/j.biopha.2025.118215_bib43","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13039-020-00517-y","article-title":"Detailed molecular cytogenetic characterisation of the myeloid cell line U937 reveals the fate of homologous chromosomes and shows that centromere capture is a feature of genome instability","volume":"13","author":"MacKinnon","year":"2020","journal-title":"Mol. Cytogenet"},{"issue":"4","key":"10.1016\/j.biopha.2025.118215_bib44","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/1098-2264(2000)9999:9999<::AID-GCC1040>3.0.CO;2-Z","article-title":"Cytogenetic and molecular analysis of the acute monocytic leukemia cell line THP-1 with an MLL-AF9 translocation","volume":"29","author":"Odero","year":"2000","journal-title":"Genes Chromosomes Cancer"},{"issue":"9","key":"10.1016\/j.biopha.2025.118215_bib45","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1182\/blood.V79.9.2378.2378","article-title":"Frequent mutations in the p53 gene in human myeloid leukemia cell lines","volume":"79","author":"Sugimoto","year":"1992","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.biopha.2025.118215_bib46","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1006\/excr.1996.0230","article-title":"DNA fragmentation induced by protease activation in p53-null human leukemia HL60 cells undergoing apoptosis following treatment with the topoisomerase I inhibitor camptothecin: cell-free system studies","volume":"226","author":"Shimizu","year":"1996","journal-title":"Exp. Cell Res"},{"issue":"27","key":"10.1016\/j.biopha.2025.118215_bib47","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.1038\/s41388-018-0219-y","article-title":"NF\u03baB regulates p21 expression and controls DNA damage-induced leukemic differentiation","volume":"37","author":"Nicolae","year":"2018","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.biopha.2025.118215_bib48","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41408-021-00497-1","article-title":"Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm","volume":"11","author":"Issa","year":"2021","journal-title":"Blood Cancer J."},{"issue":"2","key":"10.1016\/j.biopha.2025.118215_bib49","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.beha.2019.05.004","article-title":"Current status and new treatment approaches in TP53 mutated AML","volume":"32","author":"Hunter","year":"2019","journal-title":"Best. Pr. Res Clin. Haematol."},{"issue":"19","key":"10.1016\/j.biopha.2025.118215_bib50","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15194816","article-title":"TP53 mutation in acute myeloid leukemia: an old foe revisited","volume":"15","author":"Shin","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"24","key":"10.1016\/j.biopha.2025.118215_bib51","doi-asserted-by":"crossref","first-page":"6653","DOI":"10.1158\/1078-0432.CCR-21-2139","article-title":"Clinical trials assessing hypomethylating agents combined with other therapies: causes for failure and potential solutions","volume":"27","author":"Zavras","year":"2021","journal-title":"Clin. Cancer Res"},{"issue":"21-24","key":"10.1016\/j.biopha.2025.118215_bib52","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1101\/gad.351051.123","article-title":"LINE-1 retrotransposition and its deregulation in cancers: implications for therapeutic opportunities","volume":"37","author":"Mendez-Dorantes","year":"2023","journal-title":"Genes Dev."},{"issue":"23","key":"10.1016\/j.biopha.2025.118215_bib53","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232314610","article-title":"An epigenetic LINE-1-based mechanism in cancer","volume":"23","author":"Lavia","year":"2022","journal-title":"Int J. Mol. Sci."},{"issue":"18","key":"10.1016\/j.biopha.2025.118215_bib54","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1038\/sj.onc.1206354","article-title":"Exposure of normal and transformed cells to nevirapine, a reverse transcriptase inhibitor, reduces cell growth and promotes differentiation","volume":"22","author":"Mangiacasale","year":"2003","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.biopha.2025.118215_bib55","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3109\/03009734.2012.659294","article-title":"Cancer cell differentiation heterogeneity and aggressive behavior in solid tumors","volume":"117","author":"J\u00f6gi","year":"2012","journal-title":"Ups. J. Med Sci."},{"issue":"2","key":"10.1016\/j.biopha.2025.118215_bib56","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/nrc.2017.103","article-title":"Differentiation therapy revisited","volume":"18","author":"de Th\u00e9","year":"2018","journal-title":"Nat. Rev. Cancer"},{"issue":"22","key":"10.1016\/j.biopha.2025.118215_bib57","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14225642","article-title":"SOX4 mediates ATRA-induced differentiation in neuroblastoma cells","volume":"14","author":"Zhang","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.biopha.2025.118215_bib58","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.jhep.2013.07.009","article-title":"All-trans retinoic acid potentiates the chemotherapeutic effect of cisplatin by inducing differentiation of tumor initiating cells in liver cancer","volume":"59","author":"Zhang","year":"2013","journal-title":"J. Hepatol."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225004093?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225004093?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T15:51:40Z","timestamp":1758124300000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225004093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":58,"alternative-id":["S0753332225004093"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118215","relation":{},"ISSN":["0753-3322"],"issn-type":[{"type":"print","value":"0753-3322"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Azvudine exhibits potent differentiation-inducing effect by targeting the TERT\/p21 axis in acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118215","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118215"}}